Assessment of community pharmacists’ knowledge, attitudes,and beliefs toward drug misuse and abuse in Jordan: A Cross-sectional study
Main Article Content
Keywords
addiction, community pharmacist, drug abuse, misuse, pharmacy practice
Abstract
Background: Community pharmacists are often the first point of contact for patients seeking medications, positioning them as key stakeholders in addressing drug abuse and misuse. However, limited data exist on their readiness and perspectives in this area, particularly in Jordan.Aims: This study aimed to assess the knowledge, attitudes, and beliefs of community pharmacists regarding drug abuse, to identify potential pharmacy-based initiatives to address the issue, to examine the barriers they encounter, and to highlight opportunities for enhancing pharmacist-led interventions in controlling medication misuse. Method: A reliability-validated online survey was created and sent out through social media to the community pharmacists to fill out and gain the knowledge and practice about drug abuse and misuse. Results: Most pharmacists (90.7%) reported encountering cases of drug misuse in their workplace, with over half (51.9%) facing ten or more incidents. While some claimed to know the difference between “misuse” and “abuse,” only a certain percentage had received formal training on the topic. Despite ethical concerns, 30.6% admitting to treat suspected abusers differently, most pharmacists (92.9%) recognized their preventive role and expressed high willingness (93.8%) to receive future training. Knowledge levels were generally moderate, but practical preparedness and confidence in regulatory frameworks varied. Conclusion: In conclusion, the research highlights the need to monitor prescription and distribution processes properly; Jordanian community pharmacists demonstrate a moderate awareness of drug abuse issues and a clear willingness to engage in prevention. However, gaps in training and inconsistent attitudes highlight the need for enhanced education.
References
2. Al-Nefaei MM, Jahri GE, Majrashi EA, Sairafi ZA, Abualmakarem AG, Alqashqari WW, Muhanna KF, AL-Amri AS. Drug misused. Int. J. Med. Dev. Ctries. 2021 Jan 19;5.
3. Al-Worafi YM. Medication abuse and misuse. In: Drug Safety in Developing Countries. Academic Press; 2020:127-135.
4. Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G. Focus on over-the-counter drugs’ misuse: a systematic review on antihistamines, cough medicines, and decongestants. Front. Psychiatry. 2021 May 7; 12:657397.
5. Sobczak Ł, Goryński K. Pharmacological aspects of over-the-counter opioid drugs misuse. Molecules. 2020; 25(17):3905.
6. Abood EA, Wazaify M. Abuse and misuse of prescription and nonprescription drugs from community pharmacies in Aden City—Yemen. Subst Use Misuse. 2016; 51(7):942-947.
7. Al-Shawabkeh JD. Assessment of Jordanian pharmacists’ knowledge and awareness of liraglutide injection and their practice in counseling Obesity patients. Pharm Pract (Granada). 2024;22(4):1-13.
8. Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals. 2023 Jul 11;16(7):994.
9. Huang AS, Zeppieri M, Meyer JJ. Bimatoprost ophthalmic solution. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK576421/
10. Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals. 2023 Jul 11;16(7):994.
11. Aoun EG, Christopher PP, Ingraham JW. Emerging drugs of abuse: clinical and legal considerations. R I Med J. 2014;97(6):41.
12. Ignaszewski MJ. The epidemiology of drug abuse. J Clin Pharmacol. 2021; 61(Suppl 10):S10-S17.
13. Harvin A, Weber RJ. A primer on prescription drug abuse and the role of the pharmacy director. Hosp Pharm. 2015;50(5):423-428.
14. Liu L, Wheeler SE, Venkataramanan R, Rymer JA, Pizon AF, Lynch MJ, Tamama K. Newly emerging drugs of abuse and their detection methods: an ACLPS critical review. Am. J. Clin. Pathol. 2018 Jan 29;149(2):105-16.
15. Smith MF, Hiller HC. Influence of drug abuse on human health in United States of America. AJOEI. 2021 Dec 12; 3(11):16-28.
16. Teoh L, Moses G, McCullough MJ. Oral manifestations of illicit drug use. Aust Dent J. 2019;64(3):213-222.
17. Hoppe D, Ristevski E, Khalil H. The attitudes and practice strategies of community pharmacists towards drug misuse management: a scoping review. J Clin Pharm Ther. 2020; 45(3):430-452.
18. Geise R, Powers MF. Roles of pharmacy technicians in preventing prescription drug abuse. J Pharm Technol. 2020; 36(5):211-217.
19. Al-Shawabkeh J, Laban NA, Hasan D, Alsarhan A, Alzayyat A, Al-Smadi S, Ababneh S, Taha R. An observational study of post-vaccination symptoms of inactivated virus vaccine versus mRNA COVID-19 vaccine. Trop. J. Pharm. Res. 2024 Nov 19; 23(10):1749-59.
20. Al-Shawabkeh JD, Shoiab AA, Alsarhan AA, et al. Highlighted in the public knowledge, awareness, and practice (KAP) towards COVID-19 after almost one year: a cross-sectional study. Lat Am J Pharm. 2025; 44:129-140.
21. Al-Shawabkeh JD, Laban NA, Husein NA, Jaber D. Knowledge and practice in Jordan regarding the outbreak and prevention of COVID-19: a questionnaire-based study. Trop J Pharm Res. 2023; 22(4):847-857.
22. Mobrad AM, Alghadeer S, Syed W, Al-Arifi MN, Azher A, Almetawazi MS, Babelghaith SD. Knowledge, attitudes, and beliefs regarding drug abuse and misuse among community pharmacists in Saudi Arabia. Int. J. Environ. Res. Public Health. 2020 Feb; 17(4):1334.
23. Jaber D, Bulatova N, Suyagh M, Yousef AM, Wazaify M. Knowledge, attitude and opinion of drug misuse and abuse by pharmacy students: a cross-sectional study in Jordan. Trop J Pharm Res. 2015 Sep 14; 14 (8):1501-8.
24. Al-Arifi MN. Community pharmacist perception and attitude toward ethical issues at community pharmacy setting in central Saudi Arabia. Saudi Pharm. J. 2014 Sep 1; 22(4):315-25.
25. Al-Mohamadi, A.; Badr, A.; Mahfouz, L.B.; Samargandi, D.; Al-Ahdal, A. Dispensing medications without prescription at Saudi community pharmacy: Extent and perception. Saudi Pharm. J. 2013, 21, 13–18.
26. Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B. Knowledge, perceptions and attitudes toward chronic pain and its management: a cross-sectional survey of frontline pharmacists in Ontario, Canada. PLoS One. 2016 Jun 7; 11(6):e0157151.
27. Albsoul-Younes A, Wazaify M, Yousef AM, Tahaineh L. Abuse and misuse of prescription and OTC drugs at community pharmacies in Jordan: a cross-sectional study. Pharm World Sci. 2010; 32(4):446-451.
28. Almaaytah A, Mukattash TL, Hajaj J. Dispensing of non-prescribed antibiotics in Jordan. Patient Prefer. Adherence. 2015:1389-1395.
29. Al-Husseini A, Wazaify M, Van Hout MC. Pregabalin misuse and abuse in Jordan: a qualitative study of user experiences. Int J Ment Health Addict. 2018; 16(3):642-654.
30. Al-Khalaileh W, Abu-Farha R, Wazaify M, Van Hout MC. Ophthalmic drug abuse: an observational study from community pharmacies. Res Social Adm Pharm. 2019; 15(8):943-948.
31. Abu-Farha R, Gharaibeh L, Alzoubi KH, Ahmad RE, Binsaleh AY, Shilbayeh SA, El-Dahiyat F, Halboup AM. Assessment of community pharmacists’ experiences and perceptions on gabapentin abuse in Jordan: a cross-sectional study. J Pharm Policy Pract. 2024 Dec 31;17(1):2430445.
32. Al-Shawabkeh JD, Laban NM, Shawagfeh MT, et al. Community pharmacists’ current safe practice and educational needs in dispensing melatonin supplements in Jordan: a cross-sectional study. Pharm Pract (Granada). 2025; 23(2):1-1.
33. Hamer AM, Spark MJ, Wood PJ, Roberts E. The upscheduling of combination analgesics containing codeine: the impact on the practice of pharmacists. Res Social Adm Pharm. 2014;10(4):669-678.
34. Sheridan J, Butler R. Prescription drug misuse in New Zealand: challenges for primary health care professionals. Res Social Adm Pharm. 2011;7(3):281-293.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.